Legend Assets Non Current vs Current Liabilities Analysis
LEGN Stock | USD 48.83 1.29 2.57% |
Trend analysis of Legend BiotechCorp balance sheet accounts such as Total Stockholder Equity of 1.3 B provides information on Legend BiotechCorp's total assets, liabilities, and equity, which is the actual value of Legend BiotechCorp to its prevalent stockholders. By breaking down trends over time using Legend BiotechCorp balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.
Legend |
About Legend Balance Sheet Analysis
Balance Sheet is a snapshot of the financial position of Legend BiotechCorp at a specified time, usually calculated after every quarter, six months, or one year. Legend BiotechCorp Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Legend BiotechCorp and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Legend currently owns. An asset can also be divided into two categories, current and non-current.
Legend BiotechCorp Balance Sheet Chart
Legend BiotechCorp Balance Sheet is one of the main financial statements that report all assets, liabilities, and shareholders' equity for the current year. It provides a basis for different types of computing rates of return, such as return on equity (ROE) or return on asset (ROA), as well as shows how Legend BiotechCorp uses and utilizes its capital. It also shows what exactly a company owns and owes.
At this time, Legend BiotechCorp's Inventory is very stable compared to the past year. As of the 18th of April 2024, Other Stockholder Equity is likely to grow to about 2.8 B, while Total Assets are likely to drop about 938.8 M. Add Fundamental
Total Assets
Total assets refers to the total amount of Legend BiotechCorp assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Legend BiotechCorp books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.Total Current Liabilities
Total Current Liabilities is an item on Legend BiotechCorp balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Legend BiotechCorp are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.Most indicators from Legend BiotechCorp's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Legend BiotechCorp current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Legend BiotechCorp. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in price. To learn how to invest in Legend Stock, please use our How to Invest in Legend BiotechCorp guide.As of the 18th of April 2024, Selling General Administrative is likely to grow to about 112.1 M, while Tax Provision is likely to drop about 268.9 K.
2021 | 2022 | 2023 | 2024 (projected) | Other Operating Expenses | 462.8M | 575.1M | 727.4M | 365.7M | Total Revenue | 89.8M | 117.0M | 285.1M | 299.4M |
Legend BiotechCorp fundamental ratios Correlations
Click cells to compare fundamentals
Legend BiotechCorp Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Legend BiotechCorp fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 287.7M | 721.0M | 1.1B | 1.3B | 1.8B | 938.8M | |
Other Current Liab | 70.9M | 99.2M | 211.4M | 260.9M | 140.1M | 147.9M | |
Total Current Liabilities | 127.8M | 161.2M | 280.3M | 297.8M | 216.4M | 203.5M | |
Total Stockholder Equity | (122.9M) | 280.3M | 471.2M | 744.3M | 1.3B | 1.3B | |
Other Liab | 277.8M | 277.7M | 244.8M | 7.9M | 7.1M | 6.7M | |
Net Tangible Assets | (123.4M) | 277.4M | 466.5M | 740.9M | 852.0M | 894.6M | |
Retained Earnings | (127.3M) | (430.8M) | (817.0M) | (966.5M) | (1.5B) | (1.4B) | |
Accounts Payable | 9.6M | 5.2M | 7.0M | 32.9M | 20.2M | 13.6M | |
Cash | 83.4M | 455.7M | 688.9M | 786.0M | 1.3B | 1.3B | |
Other Assets | 665K | 4.2M | 7.3M | 67.7M | 1.0 | 0.95 | |
Cash And Short Term Investments | 158.9M | 505.7M | 882.4M | 1.0B | 1.3B | 1.4B | |
Net Receivables | 35.8M | 85.0M | 63.2M | 90K | 157.1M | 164.9M | |
Inventory | 1.2M | 1.8M | 1.7M | 10.4M | 19.4M | 20.4M | |
Other Stockholder Equity | 3.9M | 430.8M | 817.0M | 744.3M | 2.6B | 2.8B | |
Total Liab | 410.6M | 440.8M | 647.2M | 586.7M | 589.9M | 522.0M | |
Total Current Assets | 207.1M | 592.9M | 948.8M | 1.1B | 1.5B | 770.5M | |
Intangible Assets | 5.1M | 7.7M | 4.7M | 3.4M | 155.3M | 163.0M | |
Property Plant Equipment | 79.4M | 121.1M | 152.9M | 160.8M | 184.9M | 100.7M | |
Short Long Term Debt Total | 6.1M | 3.4M | 123.0M | 284.5M | 328.7M | 345.1M | |
Property Plant And Equipment Net | 75.5M | 121.3M | 155.1M | 161.7M | 189.7M | 135.0M | |
Current Deferred Revenue | 46.3M | 55.3M | 60.9M | 451K | 53.0M | 34.2M | |
Net Debt | (77.3M) | (452.3M) | (566.0M) | (501.5M) | (949.4M) | (901.9M) | |
Non Current Assets Total | 80.6M | 128.1M | 169.6M | 231.8M | 350.8M | 194.9M | |
Non Currrent Assets Other | 665K | 4.0M | 5.1M | 66.8M | 152.4M | 160.0M | |
Common Stock Shares Outstanding | 132.0M | 118.2M | 140.9M | 159.0M | 176.1M | 151.5M | |
Short Term Investments | 75.6M | 50M | 193.5M | 239.6M | 31.0M | 29.5M | |
Liabilities And Stockholders Equity | 287.7M | 721.0M | 1.1B | 1.3B | 1.8B | 1.1B | |
Non Current Liabilities Total | 282.8M | 279.6M | 366.9M | 288.9M | 373.5M | 339.7M | |
Capital Lease Obligations | 6.1M | 3.4M | 2.5M | 23.6M | 47.3M | 49.7M | |
Other Current Assets | 11.3M | 580.7M | 1.4M | 1.1B | 12.2M | 11.6M | |
Net Invested Capital | (122.9M) | 280.3M | 591.7M | 1.0B | 1.5B | 1.6B | |
Property Plant And Equipment Gross | 74.8M | 116.5M | 155.1M | 161.7M | 224.7M | 140.2M | |
Accumulated Other Comprehensive Income | (122.9M) | 280.2M | 471.2M | 744.3M | 98.9M | 94.0M | |
Net Working Capital | 79.3M | 431.7M | 668.5M | 801.3M | 1.3B | 1.3B | |
Short Term Debt | 1.0M | 1.5M | 911K | 3.6M | 3.2M | 1.9M |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Legend BiotechCorp. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in price. To learn how to invest in Legend Stock, please use our How to Invest in Legend BiotechCorp guide.Note that the Legend BiotechCorp information on this page should be used as a complementary analysis to other Legend BiotechCorp's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the USA ETFs module to find actively traded Exchange Traded Funds (ETF) in USA.
Complementary Tools for Legend Stock analysis
When running Legend BiotechCorp's price analysis, check to measure Legend BiotechCorp's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Legend BiotechCorp is operating at the current time. Most of Legend BiotechCorp's value examination focuses on studying past and present price action to predict the probability of Legend BiotechCorp's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Legend BiotechCorp's price. Additionally, you may evaluate how the addition of Legend BiotechCorp to your portfolios can decrease your overall portfolio volatility.
Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites |
Is Legend BiotechCorp's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Legend BiotechCorp. If investors know Legend will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Legend BiotechCorp listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.94) | Revenue Per Share 1.619 | Quarterly Revenue Growth 1.876 | Return On Assets (0.17) | Return On Equity (0.52) |
The market value of Legend BiotechCorp is measured differently than its book value, which is the value of Legend that is recorded on the company's balance sheet. Investors also form their own opinion of Legend BiotechCorp's value that differs from its market value or its book value, called intrinsic value, which is Legend BiotechCorp's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Legend BiotechCorp's market value can be influenced by many factors that don't directly affect Legend BiotechCorp's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Legend BiotechCorp's value and its price as these two are different measures arrived at by different means. Investors typically determine if Legend BiotechCorp is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Legend BiotechCorp's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.